LYMPHOMA, B-CELL

This Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…

This study tests a new treatment called JNJ-90014496 (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target two markers on cancer cells (CD19 and CD20). Th…

This early-stage trial tests a new drug called BTM-3566 in 24 adults whose B-cell lymphoma has returned or stopped responding to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can slow or stop the cancer. Participants take the drug in…

This early-stage study tests a new treatment called UB-VV111 given with the drug rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have returned or not responded to standard therapy. The study will enroll about 10…

This early-stage study is testing two experimental drugs (iberdomide and CC-99282) added to standard chemotherapy for people with untreated aggressive B-cell lymphoma. About 224 adults will take part to find the safest dose and see if the combinations help shrink tumors. The goal…

This study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 participants will take the drug alone, first in…

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will either get early palliative care plus standard care or standard care alone. Resea…

This study looks at whether a new blood test (ctDNA) can guide doctors to safely give less chemotherapy to certain patients with a type of lymphoma called DLBCL. About 40 newly diagnosed patients will have their blood tested during standard treatment. If the test shows no cancer …

This study tests a new training program called Hematolo-GIST that helps doctors communicate more clearly with patients who have large B-cell lymphoma. The goal is to improve how doctors discuss the diagnosis and plan future care. About 48 people, including doctors and patients, w…

This study watches how older patients (age 60 and up) with certain blood cancers handle standard CAR-T cell therapy and how it changes their daily life and thinking skills. No extra treatment is given—just careful checkups. The goal is to see if patients can complete all planned …

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check heart function in 60 patients before and a few days after treatment. The goal is to find out how often these heart is…

This study looks at why some families have more blood cancers like lymphoma, leukemia, and myeloma. Researchers will study the genes and environment of 3000 people who have at least two living relatives with these cancers. The goal is to find inherited factors that raise risk, no…